Detection and monitoring of dd-cfDNA in patients following kidney transplantation
One severe complication following solid organ transplantation is antibody- and/or cell-mediated rejections of the graft. Early detection of rejection may therefore be of paramount importance to improve graft survival following solid organ transplantation. The present study was conducted to determine the monitoring capability and clinical utility of the Devyser assay designed for the sensitive detection of dd-cfDNA (donor-derived cell-free DNA) in patients following kidney transplantation.
Get access by filling out the form below
Related content
View allDevyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
Read More
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
Read More
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
Read More